Silence Therapeutics plc
Price Action
Technical Summary
EMERGING TRENDSilence Therapeutics plc is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 78), indicating performance broadly in line with the market. Earnings contraction of 130% provides fundamental context to the price action. Investors should exercise caution due to high volatility (74% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $7.26 | -4.30% | BELOW |
| 50 SMA | $6.47 | +7.46% | ABOVE |
| 100 SMA | $5.97 | +16.39% | ABOVE |
| 150 SMA | $6.13 | +13.30% | ABOVE |
| 200 SMA | $5.94 | +16.92% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SLN in an uptrend right now?
SLN has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is SLN overbought or oversold?
SLN's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is SLN outperforming the market?
SLN has a Relative Strength (RS) Rating of 78 out of 99. SLN is performing about average compared to the market.
Where is SLN in its 52-week range?
SLN is trading at $6.95, which is 83% of its 52-week high ($8.40) and 70% above its 52-week low ($3.54).
How volatile is SLN?
SLN has a Beta of 0.82 and 52-week volatility of 74%. It's less volatile than the S&P 500 - generally more stable.